Predictors of functional outcome in patients with major depression and bipolar disorder: A dynamic network approach to identify distinct patterns of interacting symptoms.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 02 02 2022
accepted: 13 10 2022
entrez: 15 2 2023
pubmed: 16 2 2023
medline: 18 2 2023
Statut: epublish

Résumé

The purpose of this study is to use a dynamic network approach as an innovative way to identify distinct patterns of interacting symptoms in patients with Major Depressive Disorder (MDD) and patients with Bipolar Type I Disorder (BD). More precisely, the hypothesis will be testing that the phenotype of patients is driven by disease specific connectivity and interdependencies among various domains of functioning even in the presence of underlying common mechanisms. In a prospective observational cohort study, hundred-forty-three patients were recruited at the Psychiatric Clinic "Villa dei Gerani" (Catania, Italy), 87 patients with MDD and 56 with BD with a depressive episode. Two nested sub-groups were treated for a twelve-week period, which allowed us to explore differences in the pattern of symptom distribution (central vs. peripheral) and their connectedness (strong vs weak) before (T0) and after (T1) treatment. All patients underwent a complete neuropsychological evaluation at baseline (T0) and at T1. A network structure was computed for MDD and BD patients at T0 and T1 from a covariance matrix of 17 items belonging to three domains-neurocognitive, psychosocial, and mood-related (affective) to identify what symptoms were driving the networks. Clinically relevant differences were observed between MDD and BD, at T0 and after 12 weeks of pharmacological treatment. At time T0, MDD patients displayed an affective domain strongly connected with the nodes of psychosocial functioning, while direct connectivity of the affective domain with the neurocognitive cluster was absent. The network of patients with BD, in contrast, revealed a cluster of highly interconnected psychosocial nodes but was guided by neurocognitive functions. The nodes related to the affective domain in MDD are less connected and placed in the periphery of the networks, whereas in BD they are more connected with psychosocial and neurocognitive nodes. Noteworthy is that, from T0 to T1 the "Betweenness" centrality measure was lower in both disorders which means that fewer "shortest paths" between nodes pass through the affective domain. Moreover, fewer edges were connected directly with the nodes in this domain. In MDD patients, pharmacological treatment primarily affected executive functions which seem to improve with treatment. In contrast, in patients with BD, treatment resulted in improvement of overall connectivity and centrality of the affective domain, which seems then to affect and direct the overall network. Though different network structures were observed for MDD and BD patients, data suggest that treatment should include tailored cognitive therapy, because improvement in this central domain appeared to be fundamental for better outcomes in other domains. In sum, the advantage of network analysis is that it helps to predict the trajectory of future phenotype related disease manifestations. In turn, this allows new insights in how to balance therapeutic interventions, involving different fields of function and combining pharmacological and non-pharmacological treatment modalities.

Identifiants

pubmed: 36791083
doi: 10.1371/journal.pone.0276822
pii: PONE-D-22-00835
pmc: PMC9931103
doi:

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0276822

Informations de copyright

Copyright: © 2023 Platania et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2011;6(11):e27407
pubmed: 22114671
J Clin Psychiatry. 2007 Jul;68(7):1078-86
pubmed: 17685745
PLoS One. 2016 Dec 8;11(12):e0167490
pubmed: 27930698
Med Sci Monit Basic Res. 2017 Nov 16;23:362-367
pubmed: 29142191
J Affect Disord. 2020 Mar 15;265:278-286
pubmed: 32090752
Behav Res Ther. 2016 Nov;86:95-104
pubmed: 27424882
Behav Brain Sci. 2010 Jun;33(2-3):137-50; discussion 150-93
pubmed: 20584369
Bipolar Disord. 2020 Mar;22(2):128-138
pubmed: 31729789
Biol Psychiatry. 2000 Oct 1;48(7):674-84
pubmed: 11032979
Int J Neuropsychopharmacol. 2017 Aug 1;20(8):670-680
pubmed: 28498954
Psychol Med. 2014 Jul;44(10):2029-40
pubmed: 24168753
Psychol Med. 2017 Dec;47(16):2767-2776
pubmed: 28625186
Psychother Psychosom. 2019;88(2):71-83
pubmed: 30889609
Braz J Psychiatry. 2016 Jul-Sep;38(3):201-6
pubmed: 26870909
World J Biol Psychiatry. 2000 Apr;1(2):65-74
pubmed: 12607202
Psychol Med. 2021 Jun 24;:1-10
pubmed: 34165065
Bipolar Disord. 2001 Jun;3(3):106-50; discussion 151-3
pubmed: 11465675
Lancet. 2016 May 21;387(10033):2145-2154
pubmed: 26520231
Neuropsychiatr Dis Treat. 2019 May 10;15:1249-1258
pubmed: 31190831
World Psychiatry. 2017 Feb;16(1):5-13
pubmed: 28127906
PLoS One. 2020 Mar 23;15(3):e0230194
pubmed: 32203535
Annu Rev Clin Psychol. 2013;9:91-121
pubmed: 23537483
J Affect Disord. 2019 Apr 15;249:175-182
pubmed: 30772745
Neuropsychiatr Dis Treat. 2020 Feb 28;16:589-595
pubmed: 32184600
Rev Med Chil. 2010 Jun;138(6):773-9
pubmed: 20919490
Front Psychol. 2020 May 06;11:857
pubmed: 32435223
Neuropsychologia. 2010 May;48(6):1862-8
pubmed: 20176041
J Affect Disord. 2014 Jun;162:134-41
pubmed: 24767018
Psychother Psychosom. 2000;69(1):2-18
pubmed: 10601830
Psychiatry Res. 2018 Nov;269:157-171
pubmed: 30149273
CNS Spectr. 2019 Feb;24(1):22-29
pubmed: 30468135
Front Psychiatry. 2018 Dec 04;9:655
pubmed: 30564155
Psychol Med. 1997 Nov;27(6):1277-85
pubmed: 9403899
Bipolar Disord. 2007 Jun;9(4):413-25
pubmed: 17547587
Soc Psychiatry Psychiatr Epidemiol. 2017 Jan;52(1):1-10
pubmed: 27921134
Bipolar Disord. 2007 Feb-Mar;9(1-2):114-25
pubmed: 17391355
Bipolar Disord. 2013 Feb;15(1):1-44
pubmed: 23237061
Front Oncol. 2021 Jun 28;11:673581
pubmed: 34262863
CNS Neurol Disord Drug Targets. 2016;15(10):1290-1298
pubmed: 27712575
Psychiatry Res. 2012 Mar 30;196(1):145-53
pubmed: 22370154
CNS Spectr. 2020 Jun;25(3):380-391
pubmed: 31060642
Encephale. 2019 Nov;45(5):433-440
pubmed: 31495550

Auteurs

Giuseppe Alessio Platania (GA)

Department of Educational Sciences, University of Catania, Catania, Italy.

Claudia Savia Guerrera (C)

Department of Educational Sciences, University of Catania, Catania, Italy.
Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.

Pierfrancesco Sarti (P)

Department of Biomedical, Metabolic and Neural Sciences-University of Modena and Reggio Emilia, Modena (MO), Italy.

Simone Varrasi (S)

Department of Educational Sciences, University of Catania, Catania, Italy.

Concetta Pirrone (C)

Department of Educational Sciences, University of Catania, Catania, Italy.

Dina Popovic (D)

Abarbanel Mental Health Center, Bat-Yam, Israel.

Andrea Ventimiglia (A)

Department of Educational Sciences, University of Catania, Catania, Italy.

Simona De Vivo (S)

Villa dei Gerani Clinic ASP3 Catania, Catania, Italy.

Rita Anna Cantarella (RA)

Department of Mental Health, ASP3 Catania, Catania, Italy.

Fabio Tascedda (F)

Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.

Filippo Drago (F)

Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy.

Santo Di Nuovo (S)

Department of Educational Sciences, University of Catania, Catania, Italy.

Chiara Colliva (C)

Azienda Unità Sanitaria Locale di Modena, Distretto di Carpi, Modena, Italy.

Filippo Caraci (F)

Department of Drug and Health Sciences, University of Catania, Catania, Italy.
Oasi Research Institute-IRCCS, Troina, Italy.

Sabrina Castellano (S)

Department of Educational Sciences, University of Catania, Catania, Italy.

Johanna M C Blom (JMC)

Department of Biomedical, Metabolic and Neural Sciences-University of Modena and Reggio Emilia, Modena (MO), Italy.
Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH